

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/795,819
		Filing Date	March 8, 2004
		First Named Inventor	BAKHUTASHVILI, Vladimir
		Art Unit	1651
		Examiner Name	Ruth A. Davis
Sheet 1	of 3	Attorney Docket Number	627-B-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	1	Nahar, et al., "Infliximab Treatment of Rheumatoid Arthritis and Chrohn's Disease", The Annals of Pharmacotherapy, Vol. 37, pgs 1256-1265 (2003)	
	2	Watanabe, et al., "Concanavalin A Induces Perforin-Mediated But Not Fas-Mediated Hepatic Injury", Hepatology, Vol. 24, No. 3, pgs 702-710 (1996)	
	3	Xiang, et al., "Prevention by rolipram of concanavalin A-induced T-cell-dependent hepatitis in mice", European Journal of Pharmacology, Vol. 367, pgs 399-404 (1999)	
	4	Dzotsenidze, et al., "The Antitoxic Effect of Plaferon LB on Pesticides in Tissue Culture Model", Annals of Biomedical Research and Education, Vol. 3, pgs 180-182 (2003)	
	5	Maisuradze, et al., "Some Aspects of Protective Effect of Plaferon LB During Bronchial Asthma", Annals of Biomedical Research and Education, Vol. 3, pgs 189-191 (2003)	
	6	Kvezereli, et al., "Effects of Plaferon LB (PLB) on concanavalin A- induced hepatitis in mice", Annals of Biomedical Research and Education, Vol. 2, pgs 133-138 (2002)	
	7	Bakradze, et al., "The Perioperative Immunocorrection by Plaferon for Colorectal Cancer Patients", Annals of Biomedical Research and Education, Vol. 2, pgs 38-41 (2002)	
	8	Chichua, et al., "Biochemical Changes in Retinal Tissue During Vitreoretinal Pathology", Annals of Biomedical Research and Education, Vol. 4, pgs 189-195 (2002)	
	9	Bach, Jean-Francois, "Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases", Arthritis Res, Vol. 4, pgs S3-S15 (2002)	
	10	Nicoletti, et al., "The Effects of a Nonimmunogenic Form of Murine Soluble Interferon-gamma Receptor on the Development of Autoimmune Diabetes in the NOD Mouse", Endocrinology, Vol. 187, No. 12, pgs 5567-5575 (2005)	

Examiner Signature	[Signature]	Date Considered	3/14/06
--------------------	-------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/795,819
		Filing Date	March 8, 2004
		First Named Inventor	BAKHUTASHVILI, Vladimir
		Art Unit	1651
		Examiner Name	Ruth A. Davis
Sheet 2	of 3	Attorney Docket Number	627-B-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAD	11	Nicoletti, et al., "Early Prophylaxis with Recombinant Human Interleukin-11 Prevents Spontaneous Diabetes in NOD Mice", Diabetes, Vol. 48, pgs 2333-2339 (1999)	
	12	Lobzhanidze, et al., "Positive Effect of Plaferon-LB on Treatment of Hodgkin's Disease - Result of Immunocorrection or Apoptosis", Annals of Biomedical Research and Education, Vol. 1, pgs 170-173 (2001)	
	13	Sharma, et al., "Usefulness of Gamma Intracoronary Radiation for Totally Occluded In-Stent Restenotic Coronary Narrowing", The American Journal of Cardiology, Vol. 91, pgs 595-597 (2003)	
	14	Jessup, et al., "Heart Failure", The New England Journal of Medicine, Vol. 348, pgs 2007-2018 (2003)	
	15	Nicoletti, et al., "Prevention and Treatment of Lethal Murine Endotoxemia by the Novel Immunomodulatory Agent MFP-14", Antimicrobial Agents and Chemotherapy, Vol. 45, No. 5, pgs 1591-1594 (2001)	
	16	Genovese, et al., "Improved Survival and Antagonistic Effect of Sodium Fusidate on Tumor Necrosis Factor Alpha in a Neonatal Mouse Model of Endotoxin Shock", Antimicrobial Agents and Chemotherapy, Vol. 40, No. 7, pgs 1733-1735 (1996)	
	17	Nicoletti, et al., "Endotoxin-Induced Lethality in Neonatal Mice is Counteracted by Interleukin-10 (IL-10) and Exacerbated by Anti-IL-10", Clinical and Diagnostic Laboratory Immunology, Vol. 4, No. 5, pgs 607-610 (1997)	
	18	Nicoletti, et al., "Protection from concanavalin A (Con A) - induced T cell dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate", Clin Exp Immunol, Vol. 110, pgs 479-484 (1997)	
	19	Mizuhara, et al., "T Cell Activation-associated Hepatic Injury: Mediation by Tumor Necrosis Factors and Protection by Interleukin 6", J. Exp. Med, Vol. 179, pgs 1529-1537 (1994)	
	20	Tiegs, et al., "A T Cell-dependent Experimental Liver Injury in Mice Inducible by Concanavalin A", J. Clin. Invest., Vol. 90, pgs 196-203 (1992)	

Examiner Signature		Date Considered	3/14/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/795,819
Filing Date	March 8, 2004
First Named Inventor	BAKHUTASHVILI, Vladimir
Art Unit	1651
Examiner Name	Ruth A. Davis
Attorney Docket Number	627-B-US

Sheet 3

of

3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RA	21	Nicoletti, et al., "Murine Concanavalin A-Induced Hepatitis is Prevented by Interleukin 12 (IL-12) Antibody and Exacerbated by Exogenous IL-12 Through an Interferon-gamma-Dependent Mechanism", Hepatology, Vol. 32, No. 4, pgs 728-733 (2000)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.